Carboplatin for Mesothelioma

Carboplatin is a second-generation platinum-based chemotherapy drug used as an alternative to cisplatin in the treatment of malignant pleural mesothelioma. Like cisplatin, carboplatin works by forming platinum-DNA adducts that crosslink DNA strands and prevent cancer cell replication. However, carboplatin was specifically designed to retain cisplatin's anti-tumor activity while reducing the severe kidney damage, hearing loss, and nausea that limit cisplatin's tolerability.¹

In mesothelioma treatment, carboplatin is primarily used in combination with pemetrexed (Alimta) as a first-line regimen for patients who cannot tolerate cisplatin. This includes elderly patients, those with pre-existing renal impairment, patients with hearing loss, and those with poor performance status who may not withstand the aggressive hydration protocol required for cisplatin. Multiple phase II trials and large retrospective analyses have demonstrated that pemetrexed plus carboplatin achieves comparable response rates and survival outcomes to the standard pemetrexed/cisplatin doublet.²

A distinguishing feature of carboplatin is its dosing methodology. Unlike most chemotherapy drugs that are dosed based on body surface area (mg/m²), carboplatin is dosed using the Calvert formula, which calculates the target area under the concentration-time curve (AUC). This approach accounts for each patient's individual kidney function (glomerular filtration rate), ensuring consistent drug exposure regardless of differences in renal clearance. For mesothelioma, the standard target is AUC 5.³

While carboplatin is generally better tolerated than cisplatin, it does have its own toxicity profile. Its dose-limiting side effect is myelosuppression — suppression of bone marrow function leading to low blood counts, particularly thrombocytopenia (low platelet counts). This requires regular blood monitoring and may necessitate dose adjustments or treatment delays.¹

Carboplatin is used in several treatment contexts for mesothelioma, always as part of a combination regimen:²

First-Line: Carboplatin + Pemetrexed

The most common carboplatin-based regimen for mesothelioma:²

• Carboplatin — AUC 5, administered as a 15–60 minute intravenous infusion on Day 1
• Pemetrexed — 500 mg/m² as a 10-minute intravenous infusion on Day 1, given before carboplatin
• Cycle length — Every 21 days for 4–6 cycles
• Vitamin supplementation — Folic acid daily and B12 every 9 weeks (same requirements as with cisplatin)

Key Clinical Evidence

Although no randomized phase III trial has directly compared carboplatin/pemetrexed to cisplatin/pemetrexed in mesothelioma, substantial evidence supports their equivalence:²

• Ceresoli phase II trial — 102 patients treated with carboplatin AUC 5 + pemetrexed achieved a median overall survival of 12.7 months and a response rate of 18.6%, comparable to the cisplatin/pemetrexed results
• MAPS trial subset analysis — Patients who received carboplatin instead of cisplatin in the MAPS trial had similar survival outcomes, supporting carboplatin as a reasonable substitution⁴
• Expanded access programs — Large real-world datasets consistently show comparable outcomes between the two platinum agents when combined with pemetrexed

Combination With Bevacizumab

Carboplatin can also be combined with pemetrexed and bevacizumab in a triplet regimen. While the MAPS trial primarily used cisplatin, some institutions substitute carboplatin in the triplet for patients with contraindications to cisplatin.⁴

Second-Line Use

Carboplatin combined with gemcitabine is used as a second-line option for patients whose mesothelioma progresses after initial pemetrexed-based therapy. Response rates in this setting are modest (10–20%) but the regimen may provide disease stabilization.⁵

Carboplatin-based regimens achieve outcomes comparable to cisplatin-based therapy in most mesothelioma patient populations:²

• Median overall survival — 12–14 months with carboplatin/pemetrexed, similar to the 12.1 months reported for cisplatin/pemetrexed
• Response rates — 18–25% objective response rate, with an additional 40–50% of patients achieving stable disease
• Tolerability advantage — Better tolerability may allow more patients to complete the planned number of treatment cycles, potentially improving real-world effectiveness
• Elderly patients — Carboplatin-based regimens are particularly valuable in patients over 70 years of age, who represent a significant proportion of mesothelioma patients due to the disease's long latency period

Carboplatin is generally better tolerated than cisplatin, but patients should be aware of its specific side effect profile and management strategies:¹

• Thrombocytopenia (low platelets) — The dose-limiting toxicity of carboplatin. Platelet counts typically reach their lowest point (nadir) around days 14–21 of each cycle. Patients should watch for unusual bruising, bleeding gums, or petechiae (tiny red spots on the skin) and report these immediately
• Neutropenia (low white blood cells) — Increases susceptibility to infections. Patients should monitor for fever (above 100.4°F/38°C), which requires immediate medical attention. Growth factor support (G-CSF) may be used in some cases
• Anemia (low red blood cells) — Fatigue, weakness, and shortness of breath may indicate treatment-related anemia. Blood transfusions or erythropoiesis-stimulating agents may be needed
• Nausea and vomiting — Carboplatin is moderately emetogenic, less so than cisplatin. A two-drug anti-emetic regimen (5-HT3 antagonist + dexamethasone) is usually sufficient
• Allergic reactions — Hypersensitivity reactions to carboplatin can develop after multiple cycles, typically after the sixth or subsequent exposure. Symptoms include rash, itching, flushing, and rarely anaphylaxis. Patients should report any unusual reactions during infusion
• Mild peripheral neuropathy — Less common and less severe than with cisplatin but can occur, particularly at cumulative doses. Numbness or tingling in hands and feet should be reported promptly